Fibrinolysis for acute myocardial infarction current status and new horizons for pharmacological reperfusion, part 1

Circulation

Volumn 103, Issue 23, 2001, Pages 2862-2866

  Armstrong, Paul W ^a   Collen, Désiré ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Drug; Fibrinolysis; Myocardial infarction

Indexed keywords

ALTEPLASE; AMEDIPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; LANOTEPLASE; MEW 9036; MONTEPLASE; PAMITEPLASE; PROUROKINASE; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE;

ACUTE HEART INFARCTION; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG STRUCTURE; FIBRINOLYTIC THERAPY; HISTORY; HUMAN; INTRACORONARY INFUSION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0035849537     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.23.2862     Document Type: Review

References (55)

1. Thrombolysis for acute myocardial infarction
2. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy
3. The origin of thrombolytic therapy
4. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy
5. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
6. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
7. Intracoronary administration of fibrinolysin in acute myocardial infarct
8. Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase in combination with transluminal recanalization
9. The fibrinolytic activity of hemolytic streptococci
10. Failed coronary thrombolysis
11. Why does thrombolysis fail? Breaking through the reperfusion ceiling
12. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction
13. Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction
14. Multicentre, randomized, comparative study of recombinant vs. natural streptokinases in acute myocardial infarct (TERIMA): Thrombolysis with recombinant streptokinase in acute myocardial infarct
15. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction
16. APSAC in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study
17. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
18. ISI-3: A randomized comparison of SK vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
19. Intravenous urokinase in acute myocardial infarction
20. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
21. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction
22. Comparison of saruplase and alteplase in acute myocardial infarction: The Study in Europe With Saruplase and Alteplase in Myocardial Infarction
23. Randomized double blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial
24. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
25. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
26. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction
27. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
28. Sixty-minute alteplase protocol: A new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction
29. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022
30. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study
31. Open, non-controlled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction
32. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction: RAPID Investigators
33. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction: The RAPID II Investigators
34. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics
35. A comparison of reteplase with alteplase for acute myocardial infarction
36. Survival outcomes one year after reperfusion therapy with either alteplase or reteplase for AMI: Results from GUSTO III trial
37. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR296-299AAAA)
38. TNK-tissue plasminogen activator in acute myocardial infarction
39. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial: Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators
40. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial: The ASSENT-1 Investigators
41. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double blind randomized trial
42. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease
43. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction
44. Intravenous NPA for the treatment of infarcting myocardium early: In-TIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction
45. Comparison of plasminogen activators
46. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA, E6010, in the treatment of acute myocardial infarction: Comparison with native t-PA
47. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi
48. 2tu-PA) in rabbits
49. 2tu-PA: CGP 42935)
50. Staphylokinase: A potent, uniquely fibrin-selective thrombolytic agent
51. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction
52. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
53. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus from-loaded alteplase in acute myocardial infarction
54. Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS)
55. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction